{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:19:40Z","timestamp":1789017580368,"version":"build-2803163510"},"reference-count":28,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Asparaginase is a key component of pediatric-inspired regimens in young adults with acute lymphoblastic leukemia (ALL). Truncation of asparaginase therapy is linked to inferior outcomes in children with ALL. However, a similar correlation in adults is lacking. Here, we studied the prevalence and risk factors associated with pegylated (PEG)-asparaginase discontinuation in young adults with ALL treated on the US intergroup Cancer and Leukemia Group B (CALGB) 10403 study and examined the prognostic impact of early discontinuation (ED) (defined as &amp;lt;4 of 5 or 6 planned doses) on survival outcomes. The analysis included 176 patients who achieved complete remission and initiated the delayed intensification (DI) cycle. The median number of PEG-asparaginase doses administered before DI was 5 (range, 1-6), with 57 (32%) patients with ED. The ED patients were older (median, 26 vs 23 years; P\u00a0= .023). Survival was apparently lower for ED patients compared with those receiving \u22654 doses, but this finding was not statistically significant (hazard ratio [HR], 1.82; 95% confidence interval [CI], 0.97-3.43; P\u00a0= .06), with corresponding 5-year overall survival (OS) rates of 66% and 80%, respectively. In patients with standard-risk ALL, the ED of PEG-asparaginase adversely influenced OS (HR, 2.3; 95% CI, 1.02-5.22; P\u00a0= .04) with a trend toward inferior event-free survival (EFS) (HR, 1.84; 95% CI, 0.92-3.67; P\u00a0= .08). In contrast, there was no impact of early PEG-asparaginase discontinuation on OS (P\u00a0= .64) or EFS (P\u00a0= .32) in patients with high-risk disease based on the presence of high-risk cytogenetics, Ph-like genotype, and\/or high white blood cell count at presentation. In conclusion, early PEG-asparaginase discontinuation is common in young adults with ALL and may adversely impact survival of patients with standard-risk ALL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007791","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T13:57:24Z","timestamp":1666360644000},"page":"196-204","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":18,"title":["The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-4498","authenticated-orcid":false,"given":"Ibrahim","family":"Aldoss","sequence":"first","affiliation":[{"name":"1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yin","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wall","sequence":"additional","affiliation":[{"name":"2Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[{"name":"3The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Claxton","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Penn State University, State College, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Foster","sequence":"additional","affiliation":[{"name":"6Department of Medicine, University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"7Clinical Research Division, University of Washington, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1093-2189","authenticated-orcid":false,"given":"Harry P.","family":"Erba","sequence":"additional","affiliation":[{"name":"8Department of Medicine, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9816-6302","authenticated-orcid":false,"given":"Mark R.","family":"Litzow","sequence":"additional","affiliation":[{"name":"9Division of Hematology, Mayo Clinic Rochester, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"10Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"11Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[{"name":"12University of Chicago Comprehensive Cancer Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali S.","family":"Advani","sequence":"additional","affiliation":[{"name":"13Taussig Cancer Institute\/Leukemia Program, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"14Department of Medicine, Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina M.","family":"Luger","sequence":"additional","affiliation":[{"name":"15Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"13","key":"2023013115350739900_bib1","first-page":"987","article-title":"How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia","volume":"135","author":"Aldoss","year":"2020","journal-title":"Blood"},{"issue":"23","key":"2023013115350739900_bib2","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2023013115350739900_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"issue":"28","key":"2023013115350739900_bib4","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1200\/JCO.2005.11.411","article-title":"Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia","volume":"23","author":"Pession","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023013115350739900_bib5","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood.2020006583","article-title":"Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia","volume":"137","author":"Gottschalk Hojfeldt","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2023013115350739900_bib6","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2012.43.2070","article-title":"Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01","volume":"31","author":"Vrooman","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023013115350739900_bib7","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A\u00a0prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023013115350739900_bib8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.2015.137380","article-title":"Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation","volume":"101","author":"van der Sluis","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2023013115350739900_bib9","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"issue":"17","key":"2023013115350739900_bib10","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1200\/JCO.19.03024","article-title":"Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group","volume":"38","author":"Gupta","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023013115350739900_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2023013115350739900_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/bloodadvances.2020002439","article-title":"Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia","volume":"5","author":"Advani","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2023013115350739900_bib13","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"20","key":"2023013115350739900_bib14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children\u2019s Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023013115350739900_bib15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/ejh.12600","article-title":"Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia","volume":"96","author":"Aldoss","year":"2016","journal-title":"Eur J Haematol"},{"issue":"1","key":"2023013115350739900_bib16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2023013115350739900_bib17","first-page":"328","article-title":"Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study","volume":"136","author":"Orvain","year":"2020","journal-title":"Blood"},{"issue":"3","key":"2023013115350739900_bib18","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1080\/10428194.2017.1349902","article-title":"PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia (dagger)","volume":"59","author":"Rausch","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"2023013115350739900_bib19","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/cam4.4281","article-title":"Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia","volume":"10","author":"Schulte","year":"2021","journal-title":"Cancer Med"},{"key":"2023013115350739900_bib20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.leukres.2017.12.013","article-title":"Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses","volume":"66","author":"Burke","year":"2018","journal-title":"Leuk Res"},{"issue":"2","key":"2023013115350739900_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JCO.19.02208","article-title":"Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age","volume":"38","author":"Rank","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023013115350739900_bib22","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1038\/s41375-021-01213-5","article-title":"Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR","volume":"35","author":"Wieduwilt","year":"2021","journal-title":"Leukemia"},{"issue":"8","key":"2023013115350739900_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"2023013115350739900_bib24","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10299","key":"2023013115350739900_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2023013115350739900_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/10428194.2019.1680839","article-title":"Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"61","author":"Derman","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"2023013115350739900_bib27","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.18.01877","article-title":"Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study","volume":"37","author":"Albertsen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"2023013115350739900_bib28","first-page":"1","article-title":"Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia","volume":"61","author":"Lanvers-Kaminsky","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/2\/196\/2031519\/blooda_adv-2022-007791-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/2\/196\/2031519\/blooda_adv-2022-007791-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T11:10:35Z","timestamp":1675163435000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/2\/196\/486858\/The-impact-of-early-PEG-asparaginase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007791","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}